



## Emflaza<sup>®</sup> (deflazacort) – Expanded indication

- On June 7, 2019, [PTC Therapeutics announced](#) the FDA approval of [Emflaza \(deflazacort\)](#) tablets and oral suspension for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.
  - Previously, Emflaza was approved for DMD in patients 5 years and older.
- The use of Emflaza in patients 2 years to less than 5 years of age is supported by the findings of efficacy and safety in patients 5 years and older with DMD.
- The recommended dose of Emflaza for all ages is approximately 0.9 mg/kg/day orally once daily.
  - If tablets are used, round up to the nearest possible dose. Any combination of the four Emflaza tablet strengths can be used to achieve this dose.
  - If the oral suspension is used, round up to the nearest tenth of a milliliter.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.